Ivermectin Does Not Reduce Risk of Covid Hospitalization, Large Study Finds

According to the results of a large clinical trial published on Wednesday, the anti-parasitic drug ivermectin, which has surged in popularity as an alternative treatment for Covid-19 despite a lack of strong research to back it up, showed no sign of alleviating the disease.

The study found that ivermectin was not a good treatment for Covid in people who had been exposed to the coronaviruses in Brazil.

David Boulware is an infectious-disease expert at the University of Minnesota.

The full data set was not published until now in The New England Journal of Medicine, after the researchers shared a summary of the results online in August.

Dr. Boulware hopes that people will dive into the details and data to steer doctors away fromivermectin.

ivermectin has been used to treat infections for a long time. Experiments on cells suggested that ivermectin might block the coronaviruses, when researchers were trying thousands of old drugs against Covid-19.

Skeptics pointed out that the experiments worked because of high concentrations of the drug. The Food and Drug Administration warned that ivermectin was not approved for use in Covid-19.

Small clinical trials were carried out around the world to see if the drug worked. In December 2020, Andrew Hill reviewed the results of 23 trials and concluded that ivermectin appeared to significantly lower the risk of death from Covid-19.

If larger trials confirmed those findings, Dr. Hill said in a presentation at the time, this really is going to be a revolutionary treatment.

The popularity of Ivermectin continued to increase. Joe Rogan promoted it on his shows. In a single week in August, insurance companies spent over two million dollars on ivermectin treatments.

After Dr. Hill published his review last summer, there were reports that many of the studies he included in the analysis were flawed. Dr. Hill published a new study in January.

Dr. Hill and his colleagues looked at the studies that were least likely to be biased. ivermectin's benefit vanished in that survey.

The best studies on ivermectin and Covid were small, with a few hundred volunteers. Small studies can be vulnerable to statistical flukes that suggest positive effects. The studies on ivermectin promised to be more rigorous.

In June 2020, researchers in Brazil will conduct a clinical trial known as TOGETHER to test Covid patients with a number of widely used drugs, including ivermectin. The treatments were double-blind, meaning that neither the patients nor their medical staff knew if they received a Covid treatment drug or a placebo.

In the first round of the trial, the researchers found that the drug fluvoxamine reduced the need for hospitalization by one-third. The results were published in October.

The TOGETHER team reported on its ivermectin data in a new study. The researchers gave the drug to 679 patients over the course of three days.

Taking ivermectin did not reduce the risk of a Covid patient ending up in the hospital.

The researchers looked at the benefits that different groups of volunteers had. It is possible that ivermectin only worked if taken early in the infection. The volunteers who took ivermectin 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020 800-361-3020

The results of the trial were very good, according to Dr. Hill. The New England Journal of Medicine took months to publish the results of the trial.

The editorial process of the journal is confidential, according to Julia Morins.

The new data from the TOGETHER trial has been included in Dr. Hill's analysis of ivermectin studies again. More than 5,000 people were included in his analysis. He didn't see any benefit from ivermectin.

Thousands of volunteers have yet to see the results of several randomized trials of ivermectin. The National Center for Advancing Translational Sciences has been running a trial of ivermectin and other drugs for Covid patients for more than a year. It hasn't released results yet.

The first batches of results from the ivermectin study will be released in two to three months, according to Dr. Sarah Dunsmore, a program director in the clinical innovations division at NCATS.

Dr. Boulware was not sure if the additional trials would come to a different conclusion since the TOGETHER trial was so large.

Dr. Boulware shared his view with Dr. Paul Sax, who was not involved in the trial.

I welcome the results of the other trials and will view them with an open mind, but at some point it will become a waste of resources to continue studying an unpromising approach.